Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Post-Approval Drug Issues
Post-Approval Drug Issues
by marina-yarberry
FDLI-Introduction to Drug Law Regulation. By: . ...
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events
by lois-ondreau
S. Percy Ivy, MD. Associate Chief, Senior Investi...
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events
FDA Final Rule & Revised NCI Guidelines for Expedited Reporting of Adverse Events
by mitsue-stanley
S. Percy Ivy, MD. Associate Chief, Senior Investi...
FDA Final Rule & Revised CTEP Guidelines for Expedited
FDA Final Rule & Revised CTEP Guidelines for Expedited
by stefany-barnette
S. Percy Ivy, MD. Associate Chief, Senior Investi...
Comments for FDA Food Advisory Committee
Comments for FDA Food Advisory Committee
by luanne-stotts
Michael Crupain, MD, MPH. Consumer Reports. Two P...
MCPAP Clarification on the FDA Celexa Warning The FDAs warning is based on reports it received of people adults taking Celexa who developed prolonged QTc
MCPAP Clarification on the FDA Celexa Warning The FDAs warning is based on reports it received of people adults taking Celexa who developed prolonged QTc
by pamella-moone
In addition a study involving 119 adults found th...
ASTER One Year Later
ASTER One Year Later
by luanne-stotts
A New Business Model for Postmarketing Reporting....
Substantial Equivalence – Where do we Stand?
Substantial Equivalence – Where do we Stand?
by tatyana-admore
Stacy Ehrlich. , Partner, Kleinfeld Kaplan & ...